Q-omics provides the consensus-scored FAM151A profile across patient tissues and cancer cell-line models. FAM151A expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, FAM151A is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, FAM151A RNA expression shows 16,247 significant gene co-expression associations, with the highest sampling consensus in PCPG. Together, these results highlight HNSC, KIRP, and PCPG as cancer lineages where FAM151A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM151A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM151A survival associations across molecular data types. FAM151A RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM151A RNA expression–survival associations across cancer types. High FAM151A expression shows unfavorable associations in UCEC, OV and LGG, but favorable associations in HNSC, ACC and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for FAM151A RNA expression.
This table summarizes FAM151A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM151A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM151A shows lower tumor expression in KIRP, COAD, THCA, KIRC and KICH and higher tumor expression in LUAD. The KIRP box plot shows higher FAM151A RNA expression in normal versus tumor tissue (log2 FC = −6.205, t-test p < 0.001).
This table shows molecular features associated with FAM151A in patient tissues and cancer cell lines. In patient samples, FAM151A shows the broadest associations at the RNA and protein expression levels, with PCPG recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM151A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BLOOD_Leukemia.
